Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata

NCT07757867 | Completed

• 1 other identifier: 35668/8/22
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.

Conditions

Microneedling-Assisted Delivery; Cetirizine; Latanoprost; Alopecia Areata

Outcome Measures

Primary Outcomes (1)

• Severity of Alopecia Tool Score (SALT Score)

  The Severity of Alopecia Tool (SALT) score was used to assess the extent of scalp hair loss. The score ranges from 0 to 100, with higher scores indicating greater scalp hair loss. Changes in SALT score from baseline was compared between the treatment groups.

  Baseline and 12 weeks

Secondary Outcomes (2)

• Global assessment of hair regrowth

  Baseline and at the end of the 12-week treatment period

• Adverse events

  Throughout the 12-week study period.

Study Arms (4)

Group A

EXPERIMENTAL

Patients treated with microneedling-aided administration of topical cetirizine 1% solution.

Drug: Cetirizine (Zyrtec)

Group B

EXPERIMENTAL

Patients treated with microneedling-aided administration of topical latanoprost 0.01% solution.

Drug: Latanoprost

group C

ACTIVE COMPARATOR

Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

Drug: Triamcinolone Acetonide

Group D

ACTIVE COMPARATOR

Patients treated with microneedling only as a negative control group

Procedure: Microneedling only

Interventions

Cetirizine (Zyrtec) DRUG

Patinets treated with microneedling-aided administration of topical cetirizine 1% solution

Group A

Latanoprost DRUG

Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

Group B

Triamcinolone Acetonide DRUG

Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group

group C

Microneedling only PROCEDURE

Patientstreated with microneedling only as a negative control group

Group D

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Newly diagnosed cases of alopecia areata.
• Patients of any age.
• Both male and female patients.
• Recent-onset patchy alopecia areata of ≤6 months' duration.
• Presence of no more than two alopecia patches.
• Stationary course of the disease.
• Willingness to participate in the study.
• Provision of written informed consent or parental/guardian consent for minors.

You may not qualify if:

• Extensive alopecia areata, including alopecia totalis or alopecia universalis.
• Previous treatment of the alopecia areata lesions.
• Active scalp infection.
• Presence of associated dermatological, systemic, or autoimmune comorbidities.
• Known allergy or hypersensitivity to any of the planned therapeutic agents.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia Governorate, Egypt, 31527, Egypt

Location

MeSH Terms

Conditions

Alopecia Areata

Interventions

Cetirizine; Latanoprost; Triamcinolone Acetonide

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Hydroxyzine; Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Autacoids; Inflammation Mediators; Biological Factors; Triamcinolone; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Dermatology and Venereology

Study Record Dates

• First Submitted: August 6, 2026
• First Posted: August 11, 2026
• Study Start: October 1, 2022
• Primary Completion: October 1, 2024
• Study Completion: October 1, 2024
• Last Updated: August 11, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.

Locations

EG (1)